154 related articles for article (PubMed ID: 34849123)
1. Assessment of serum concentrations of matrix metalloproteinase 1, matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases 1 in atopic dermatitis in correlation with disease severity and epidermal barrier parameters.
Basałygo M; Śliwiñska J; Żbikowska-Gotz M; Lis K; Socha E; Bartuzi Z; Zegarska B
Postepy Dermatol Alergol; 2021 Oct; 38(5):773-779. PubMed ID: 34849123
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of the interleukin-25 serum concentration on the intensity of the symptoms of atopic dermatitis and epidermal barrier.
Basałygo M; Śliwińska J; Żbikowska-Gotz M; Lis K; Socha E; Nowowiejska L; Bartuzi Z; Zegarska B
Postepy Dermatol Alergol; 2021 Dec; 38(6):1071-1077. PubMed ID: 35126017
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis.
Katoh N; Hirano S; Suehiro M; Ikenaga K; Yasuno H
Clin Exp Immunol; 2002 Feb; 127(2):283-8. PubMed ID: 11876751
[TBL] [Abstract][Full Text] [Related]
4. Either transepidermal water loss rates or stratum corneum hydration levels can predict quality of life in children with atopic dermatitis.
Wang S; Shen C; Zhao M; Jiao L; Tian J; Wang Y; Ma L; Man MQ
Pediatr Investig; 2021 Dec; 5(4):277-280. PubMed ID: 34938969
[TBL] [Abstract][Full Text] [Related]
5. A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis.
Harper JI; Godwin H; Green A; Wilkes LE; Holden NJ; Moffatt M; Cookson WO; Layton G; Chandler S
Br J Dermatol; 2010 Feb; 162(2):397-403. PubMed ID: 19804592
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
7. Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity.
Montero-Vilchez T; Segura-Fernández-Nogueras MV; Pérez-Rodríguez I; Soler-Gongora M; Martinez-Lopez A; Fernández-González A; Molina-Leyva A; Arias-Santiago S
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33477944
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
9. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis.
Furue M; Matsumoto T; Yamamoto T; Takeuchi S; Esaki H; Chiba T; Yamaguchi H
J Dermatol Sci; 2012 Apr; 66(1):60-3. PubMed ID: 22391243
[TBL] [Abstract][Full Text] [Related]
11. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study.
Montero-Vilchez T; Rodriguez-Pozo JA; Diaz-Calvillo P; Salazar-Nievas M; Tercedor-Sanchez J; Molina-Leyva A; Arias-Santiago S
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743415
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
16. Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis.
Bieniaś B; Sikora P
Dis Markers; 2020; 2020():9520309. PubMed ID: 32670438
[TBL] [Abstract][Full Text] [Related]
17. Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis.
Kobusiak-Prokopowicz M; Kaaz K; Marciniak D; Karolko B; Mysiak A
Kidney Blood Press Res; 2021; 46(6):749-757. PubMed ID: 34801997
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of tissue inhibitor of metalloproteinases-2 (TIMP-2) on chronic dermatitis.
Miyoshi H; Kanekura T; Aoki T; Kanzaki T
J Dermatol; 2005 May; 32(5):346-53. PubMed ID: 16043896
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their inhibitors in acute viral hepatitis.
Koulentaki M; Valatas V; Xidakis K; Kouroumalis A; Petinaki E; Castanas E; Kouroumalis E
J Viral Hepat; 2002 May; 9(3):189-93. PubMed ID: 12010506
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
